Ian Hirsch
AstraZeneca (United Kingdom)(GB)
Publications by Year
Research Areas
Asthma and respiratory diseases, SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies, Respiratory and Cough-Related Research, Eosinophilic Esophagitis
Most-Cited Works
- → Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK(2020)4,980 cited
- → Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection(2021)1,230 cited
- → Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials(2021)1,203 cited
- → Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies(2017)311 cited
- → Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma(2018)245 cited
- → Balancing benefit and risk of medicines: a systematic review and classification of available methodologies(2014)118 cited
- → Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma(2018)115 cited
- → Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials(2020)114 cited
- → The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies(2017)89 cited